RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:79492

Pili gemini

medium confidenceDisorder

Also known as: Pili multigemini

Publications

33

35.6th percentile

Trials

0

Interventional, condition-specific

Researchers

97

Distinct authors in sample

Gene link

—

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

A rare isolated hair shaft abnormality characterized by multiple hair shafts arise from a single pilosebaceous canal and emerge from a single follicular ostium. It can occur in each type of hair; mostly in bread of men or in the other uncommon locations of the body (such as the back or abdomen). Folliculitis may also be present. Most of the patients are asymptomatic, however, some may present with recurrent inflammatory lesions which can have residual atrophic or hypertrophic scars. Persisting itching is also reported in some patients.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

pili multigemini

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    33 matched papers (18 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

33

33 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

33 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

18 in the last 10 years · medium confidence · 35.6th percentile (publications denominator)

Phrase hits: 33 · MeSH hits: 1

Open Europe PMC search

Who's working on it?

97

Distinct author names in 33 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Nair PA3 papers · 2018

    Department of Dermatology and Venereology, Pramukhswami Medical College, Karamsad, Gujarat, India.

    Papers in Europe PMC
  2. 02
    Tosti A2 papers · 2015

    Department of Dermatology and Cutaneous Surgery, University of Miami L. Miller School of Medicine, Miami, Florida.

    Papers in Europe PMC
  3. 03
    Avila C1 paper · 2020
    Papers in Europe PMC
  4. 04
    Azevedo F1 paper · 2013
    Papers in Europe PMC
  5. 05
    Barbareschi M1 paper · 1995
    Papers in Europe PMC
  6. 06
    Barrett H1 paper · 2023

    Department of Histopathology, Beaumont Hospital, Dublin, Ireland.

    Papers in Europe PMC
  7. 07
    Beatty P1 paper · 2023

    Department of Dermatology, Beaumont Hospital, Dublin, Ireland.

    Papers in Europe PMC
  8. 08
    Bhat YJ1 paper · 2023

    Department of Dermatology, Venereology and Leprosy, Govt. Medical College Srinagar, Jammu and Kashmir, India.

    Papers in Europe PMC
  9. 09
    Bhide AA1 paper · 2016

    Department of Dermatology, Venereology and Leprosy, Grant Government Medical College, Mumbai, Maharashtra, India.

    Papers in Europe PMC
  10. 10
    Camacho FM1 paper · 2000

    Department of Dermatology of Seville, Hospital Universitario Virgen Macarena, Av. da Dr. Fedriani, s/n, 41009 Sevilla, Spain. camachodp@meditex.es

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Pili gemini" OR "Pili multigemini"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Pili multigemini

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Pili gemini" OR "Pili multigemini"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T02:29:59.344Z